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AIM
α1-Acid glycoprotein (AAG), which is a major binding protein of docetaxel, is considered to be a determinant for docetaxel
pharmacokinetics. However, there are no reports about the impact of serum AAG on pharmacokinetics and pharmacodynamics in
elderly patients treated with docetaxel. The aim of this prospective study was to elucidate the effects of advanced age and serum
AAG on docetaxel unbound exposure and neutropenia, dose-limiting toxicity, in cancer patients.
METHODS
Docetaxel was administered at 60 mg m2 to 51 patients with non-small cell lung cancer, 17 of whom were ≥75 years of age.
Pharmacokinetics, unbound fraction (fu), neutropenia, serum protein levels of AAG and albumin, as well as baseline absolute
neutrophil count (ANC) were assessed during the ﬁrst course. Population pharmacokinetic and pharmacodynamic analyses were
performed to evaluate the inﬂuence of clinically relevant factors on docetaxel pharmacokinetics and neutropenia.
RESULTS
Clearance of docetaxel and degree of fu were signiﬁcantly associated with serum AAG level, but not with age. Area under the
concentration–time curve of unbound docetaxel (fu·AUC) was signiﬁcantly higher in patients aged ≥75 years (0.389 μg·h ml1,
95% CI; 0.329–0.448 μg·h ml1) compared with patients aged <75 years (0.310 μg·h ml1, 95% CI; 0.268–0.352 μg·h ml1).
Percent decrease in ANC at nadir related to fu·AUC, and was dependent on baseline ANC.
CONCLUSION
Regardless of ageing, serum level of AAG determines docetaxel unbound exposure and related dose-limiting toxicity. Serum AAG
level and ANC at baseline appear to be predictive of neutropenia for patients of all ages following the administration of docetaxel.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• α1-Acid glycoprotein (AAG), which is a major binding protein of docetaxel, is regarded as a determinant for docetaxel
pharmacokinetics.
• Docetaxel-induced severe haematological toxicity occurs more frequently in the elderly, whereas there are no signiﬁcant
age-related differences in the pharmacokinetics.
WHAT THIS STUDY ADDS
• Regardless of ageing, serum AAG level that increases in cancer patients determines docetaxel unbound exposure and
related dose-limiting toxicity.
• Neutropenia can be predicted by serumAAG level and absolute neutrophil count at baseline for patients of all ages follow-
ing the administration of docetaxel.
Introduction
As the population ages, a signiﬁcant and rapidly increasing
number of older cancer patients require treatments appro-
priate for age-related physiological changes affecting
pharmacokinetics and pharmacodynamics in elderly indi-
viduals. As such, the International Society of Geriatric
Oncology published clinical practice recommendations for
dose adjustments of renally excreted cancer drugs in geriat-
ric patients [1, 2] that take into consideration the decline
in renal function with ageing [3]. Unfortunately, no dosing
information for non-renally excreted cancer drugs has been
provided for this population. Predominantly eliminated by
hepatic metabolism, docetaxel shows effective antitumor
activity against numerous tumours, and is approved for
treatment of breast cancer, non-small cell lung cancer
(NSCLC), hormone-refractory prostate cancer, gastric ade-
nocarcinoma, and squamous cell carcinoma of the head
and neck [4]. Docetaxel monotherapy is one of the stan-
dard approaches for pre-treated NSCLC patients [5, 6],
and is a ﬁrst-line treatment for older patients aged ≥70 or
75 years [7–9]. Previous reports suggesting older patients
(aged ≥65 or 75 years) were more sensitive to docetaxel-
induced neutropenia indicate the pharmacokinetics of do-
cetaxel were unaltered; however, severe haematological
toxicity was observed more frequently in the older patient
population [10, 11].
As docetaxel is extensively bound to serum proteins
(binding percentage > 90%), the concentration of un-
bound docetaxel correlates with both beneﬁcial and harm-
ful effects of the drug. According to binding parameters, it
is thought the major binding protein of docetaxel is α1-acid
glycoprotein (AAG) rather than albumin (ALB) [12]. Hence,
variability of serum AAG levels contributes to differences in
the unbound fraction and systemic clearance of docetaxel.
Area under the concentration–time curve (AUC) of total
docetaxel during the ﬁrst course and baseline serum AAG
levels have previously been shown to be independent pre-
dictors of treatment efﬁcacy in NSCLC patients [13, 14].
Moreover, ﬁrst-course total and unbound exposure of doce-
taxel, as well as baseline serum AAG levels, are related to
severity of haematological toxicity [13–16]. Based on these
pharmacokinetic and pharmacodynamic characteristics, the
aim of this study was to prospectively elucidate the effects
of advanced age and serum AAG level on docetaxel un-
bound exposure and neutropenia, a dose-limiting toxicity,
in cancer patients.
Patients and Methods
Eligibility
Patients ≥20 years of age were eligible if they had pathologi-
cally conﬁrmed NSCLC with a plan to receive docetaxel
monotherapy. Patients with interstitial pneumonitis identi-
ﬁed by chest X-ray were excluded.
Study design
The objective was to evaluate the impacts of the advanced
age and serum AAG level on unbound docetaxel exposure
and neutropenia in cancer patients. Baseline serum levels
of AAG and ALB were measured before administration of
docetaxel. US National Cancer Institute Common Termi-
nology Criteria for Adverse Events version 4.0 was used
to assess neutropenia as neutrophil counts decreased
[17]. The study duration included the ﬁrst 3-week course.
This study protocol was approved by the institutional re-
view board at Shizuoka Cancer Center in Shizuoka,
Japan, where the study was conducted. This study was
registered at the University Hospital Medical Information
Network Clinical Trials Registry (UMIN 000014701). Study
procedures were in accordance with the ethical standards
of the Declaration of Helsinki. Written informed consent
was obtained from each patient prior to enrolment.
Drug treatment
Docetaxel (Taxotere®; Sanoﬁ K.K., Japan) monotherapy was
administered over the course of 1 h at a dose of 60 mg m2
once every 3 weeks to patients with an adequate bone mar-
row reserve. Dexamethasone was administered at a dose of
8 mg before docetaxel treatment.
Pharmacokinetic sampling and assay
Blood samples were obtained ﬁve times: before infusion, just
before the end of a 1-h infusion, and at 10–60 min, 2–5 h,
and 12–24 h after the end of the infusion. Peripheral blood
samples (6 ml) were drawn into vacuumed tubes at each sam-
pling time and centrifuged at 3000 rpm for 10 min at room
temperature. Resulting serum was frozen and stored at 80°C
until analysis.
Concentration of docetaxel was determined with an
ultra-performance liquid chromatography (UPLC)-tandem
mass spectrometry technique modiﬁed from a previously
reported method [18] and developed speciﬁcally for this
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study. Docetaxel and paclitaxel, an internal standard, were
purchased from Sigma-Aldrich (St Louis, MO, USA). The
UPLC-tandem mass spectrometry system was equipped
with an Acquity UPLC system and a Xevo TQ MS spec-
trometer (Waters, Milford, MA, USA). Chromatographic
separations were obtained under gradient conditions with
an Acquity UPLC BEH C18 column (100 mm × 2.1 mm
inner diameter, 1.7 μm particle size; Waters). The mobile
phase consisted of eluent A (10 mM ammonium formate
containing 0.2% formic acid) and eluent B (acetonitrile).
The mass spectrometer was run in positive mode, and
the multiple reaction monitoring mode detected 808.7 >
Table 1
Patient demographics and characteristics
Age < 75 years Age ≥ 75 years Total
Characteristics Number of patients Median Range Number of patients Median Range number of patients
Age (years) 34 63 34–73 17 77 75–84 51
BSA (m2) 1.54 1.37–1.86 1.64 1.19–2.09
Gender
Male 28 15 43
Female 6 2 8
AAG (mg dl1) 118 71–264 128 50–249
ALB (g dl1) 3.7 2.2–4.8 3.7 2.7–4.4
AST (U l1) 26 14–76 23 15–57
ALT (U l1) 16 7–57 18 5–40
Total bilirubin (mg dl1) 0.4 0.2–1.3 0.5 0.2–0.9
Creatinine, (mg dl1) 0.73 0.42–1.56 0.69 0.44–1.72
Neutrophil counts per μl 4461 2132–9650 4001 2088–9911
ECOG performance status
0 8 2 10
1 25 15 40
2 1 0 1
Prior treatmenta
0 1 12 13
1 18 3 21
2 11 2 13
≥3 4 0 4
Smoking status
Smoker 28 13 41
Never-smoker 6 4 10
Histology
Adenocarcinoma 28 12 40
Squamous cell carcinoma 5 4 9
Others 1 1 2
EGFRmutation status
Mutant 7 1 8
Wild 24 12 36
Unknown 3 4 7
AAG, α1-acid glycoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSA, body surface area; ECOG, Eastern
Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
aP < 0.05
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226.2 and 854.7 > 105.0 for docetaxel and paclitaxel, re-
spectively. Chromatographic data were acquired and
analysed with MassLynx equipped with QuanLynx
(Waters).
Concentration of docetaxel in patient serum samples was
calculated by determining the ratio of the area of docetaxel to
the area of the internal standard in each sample and by com-
paring these ratios to a standard curve prepared on the same
day as the samples. The concentration range of standard
curves was 10–4000 ng ml1. The bias and precision of qual-
ity control samples were less than 15%. At the lower limit of
assay quantitation, bias and precision were less than 20%,
as per guidelines provided in the Food and Drug Administra-
tion (FDA) Guidance for Industry Bioanalytic Method Valida-
tion [19]. Interday and intraday variabilities in precision
(expressed as the coefﬁcient of variation) ranged from 9.2%
to 11.8% and from 2.9% to 8.1%, respectively. Average accu-
racies ranged from 92.3% to 98.3%.
The unbound fraction of docetaxel in serum 10–60 min
after the end of infusion was obtained by equilibrium dialy-
sis, which was conducted in a shaking incubator at 37°C for
6 h using 96-well microdialysis plates (HTD96b, HTDialysis,
CT, USA). The dialysis compartments in each well were sepa-
rated by a regenerated cellulose membrane (Dialysis Mem-
brane Strips MWCO 12-14 kDa, HTDialysis). Experiments
were carried out with 150-μl plasma aliquots in an equal vol-
ume of Dulbecco’s Phosphate Buffered Saline (Wako Pure
Chemical Industries, Osaka, Japan).
Population pharmacokinetic (PPK) analysis
PPK analysis was performed with NONMEM version 7.3.0
(PDx-POP 4.10; ICON Development Solutions, Dublin,
Ireland). The pharmacokinetic model was a two-
compartment structural model with ﬁrst order elimination
(subroutines ADVAN3 and TRANS3). Basic pharmacokinetic
parameters of docetaxel included total body clearance (CL),
volumes of distribution of the central compartment (Vc)
and at steady state (Vss), and intercompartmental clearance
(Q). AUC was computed as AUC = Dose/CL.
Interindividual variability was assumed to obey a log-
normal distribution and is described for each parameter as
follows:
θj ¼ θ exp ηjð Þ (1)
Figure 1
Concentration–time proﬁle of docetaxel in 51 patients. (○) patients
aged <75 years, and (●) aged ≥75 years
Figure 2
Relationships between total body clearance of docetaxel and age (A),
α1-acid glycoprotein (AAG) level (B), and albumin (ALB) level (C)
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where ηj is the random effect for individual j, θ is the popula-
tion mean parameter, and η is a random variable with mean
zero and variance ω2. Residual variability was described by a
proportional error model as follows:
Ci;j ¼ Cpredi;j exp εi;j
 
(2)
where Cpredi, j is the ith model-predicted concentration for
patient j, Ci, j is the measured concentration, and εi, j denotes
the residual intraindividual random error.
Demographic variables of age, as well as serum levels of
AAG and ALB, were examined to identify whether these vari-
ables could explain the observed substantial interindividual
variability. Demographic variables, which were considered
continuous, were included one at a time by stepwise selection
based on a likelihood ratio test. Minimum values of the
NONMEM objective function were used as a statistic for
choosing suitable models during the model-building process.
Potentially signiﬁcant covariates were identiﬁed as factors
that, when added to the basic model individually, resulted in
a decrease in the objective function of 3.84 ormore (P< 0.05).
Exposure-toxicity analysis
The percent decrease in absolute neutrophil count (ANC) was
deﬁned as:
Percent decrease in ANC ¼ Pretreatment ANCNadir ANC
Pretreatment ANC
100
(3)
and the relationship between percent decrease in ANC at na-
dir and unbound AUC (fu·AUC) of docetaxel was described by
a sigmoid Emax model:
Percent decrease in ANC ¼ Emax fu·AUC½ 
γ
EC50
γ þ fu·AUC½ γ (4)
where Emax represents the maximal effect and EC50 is the
fu·AUC value at which 50% of the maximum effect occurs.
The exponent γ is a shape factor that determines the steep-
ness of the response curve. Covariates capable of affecting
Emax and EC50 were tested for age, gender and baseline ANC
by univariate and multivariate analyses. Computations were
made using NONMEM.
Table 2
Final estimates of population pharmacokinetics and exposure-toxicity parameters of total docetaxel
Parameters Estimate Standard error of estimate 95% Conﬁdence interval
Population pharmacokinetics
CL (l h1) = θ1*BSA*(AAG/121)
θ2
θ1 14.5 0.516 13.5, 15.5
θ2 0.495 0.0816 0.655, 0.335
Vc (l) = θ3*(ALB/3.7)
θ4
θ3 8.89 0.403 8.10, 9.68
θ4 0.550 0.185 0.913, 0.187
Vss (l) 129 8.28 113, 145
Q (l h1) 11.0 0.542 9.94, 12.1
Interindividual variability
ω2CL 0.0426 0.00903 0.0249, 0.0603
ω2Vc 0.00885 0.00923 0, 0.0269
ω2Vss 0.0176 0.00987 0, 0.0369
Intraindividual variability
σ2 0.0360 0.00598 0.0243, 0.0477
Exposure-toxicity relationship for neutropenia
Emax (%) 84.5 2.13 80.3, 88.7
EC50 (μg·h ml
1): Baseline ANC > 4341 0.142 0.00267 0.137, 0.147
EC50 (μg·h ml
1): Baseline ANC ≤ 4341 0.101 0.0159 0.0698, 0.132
Shape parameter, γ 3.72 0.518 2.70, 4.74
Residual variability 0.0164 0.00531 0.00599, 0.0268
AAG, α1-acid glycoprotein level; ALB, albumin level; ANC, absolute neutrophil count; BSA, body surface area; CL, total body clearance; Emax, maxi-
mum effect on percent decrease in absolute neutrophil counts; EC50, fu·AUC value that causes 50% of the maximum effect; Q, inter-compartmental
clearance; Vc, volume of distribution of the central compartment; Vss, volume of distribution at steady state; ω
2, variance of interindividual variability
of parameters; σ2, variance of intraindividual variability.
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Statistical analysis
All categorical variables were analysed using a chi-square or
Fisher’s exact test, as appropriate. Continuous variables be-
tween two groups were analysed using the Mann–Whitney
U-test. Linear regression analysis was used to evaluate the as-
sociation between continuous variables and docetaxel
pharmacokinetic parameters. All P-values were reported as
two-sided and values < 0.05 were considered statistically
signiﬁcant.
Nomenclature of targets and ligands
Key ligands in this article are hyperlinked to corresponding
entries in http://www.guidetopharmacology.org, the com-
mon portal for data from the IUPHAR/BPS Guide to PHAR-
MACOLOGY [20].
Results
Between August 2014 andMay 2015, 51 Japanese patients (34
aged<75 and 17 aged ≥75 years) were enrolled into this study.
All patients were assessable for pharmacokinetics, and 49
patients were also evaluated for neutropenia because two
patients were excluded due to prophylactic administration
of granulocyte colony-stimulating factor (CSF). Patient
demographics and characteristics listed in Table 1 were
similar between patients aged <75 years and patients aged
≥75 years, except for the number of prior treatments. Older
patients had received fewer previous chemotherapies
(P < 0.0001). No signiﬁcant differences in serum levels of
AAG and ALB, or ANC at baseline existed between the two
cohorts.
Pharmacokinetics
Serum concentration–time proﬁles of total docetaxel in
patients aged ≥75 years and <75 years are shown in
Figure 1. Individual CL was plotted against a patient’s factors
to examine any correlations (Figure 2). A moderate associa-
tion was observed between decreased CL and increased age
(R2 = 0.086, P < 0.05; Figure 2A), whereas strong correlations
existed between CL and serum AAG level (R2 = 0.505,
P < 0.0001; Figure 2B) and inversely between CL and serum
ALB level (R2 = 0.483, P < 0.0001; Figure 2C). According to
univariate analyses, CL, Vc and Vss of docetaxel were signiﬁ-
cantly associated with serum levels of both AAG and ALB
(P < 0.001), but not with age (Table S1). Multivariate analysis
showed that serum AAG level was the only signiﬁcant factor
affecting CL of docetaxel (P < 0.001; Table S1). However,
serum ALB level was signiﬁcantly associated with Vc
(P < 0.005; Table S1). Estimated PPK parameters are summa-
rized in Table 2.
Pharmacokinetic parameters in patients aged <75 years
and ≥75 years of age are listed in Table 3. Total docetaxel
pharmacokinetic parameters, including Cmax, Vc and Vss,
were not different between the two cohorts. CL per individual
(l h1) was signiﬁcantly higher in patients aged <75 years
(P < 0.05); however, CL per body surface area (l h1 m2)
was not signiﬁcantly different between the two cohorts. Total
docetaxel AUC and degree of unbound fraction (fu) were
higher in patients aged ≥75 years (4.49 ± 1.19 μg·h ml1 and
8.9 ± 2.1%, respectively) than in patients aged <75 years
(4.09 ± 1.28 μg·h ml1 and 7.8 ± 2.7%, respectively). How-
ever, this observation did not reach a level of statistical signif-
icance (P = 0.084 and P = 0.071, respectively). But fu·AUC,
which was calculated as the product of total AUC and un-
bound fraction, was signiﬁcantly higher in older patients
(0.389 ± 0.114 μg·h ml1) than in other patients (0.310 ±
0.121 μg·h ml1, P < 0.05).
Unbound fraction
Degree of unbound fraction varied from 3.1% to 15.6% (me-
dian = 8.1%) in 51 patients, as shown in Figure 3A. There
was no association between degree of unbound fraction and
age (R2 = 0.042; Figure 3B), in accordance with no signiﬁcant
Table 3
Pharmacokinetic parameters and incidence of neutropenia
Age <
75 years
Age ≥
75 years
Pharmacokinetic parameters n = 34 n = 17
Total docetaxel
Cmax (μg ml
1) 1.76 ± 0.60 2.17 ± 1.18
AUC (μg·h ml1) 4.09 ± 1.28 4.49 ± 1.19
CL (l h1) 25.12 ± 5.98 21.49 ± 4.84*
CL (l h m2) 15.65 ± 3.92 13.87 ± 3.30
Vc (l) 9.05 ± 1.00 9.19 ± 0.86
Vc (l m
2) 5.66 ± 0.87 5.97 ± 0.87
Vss (l) 129.47 ± 9.09 126.37 ± 9.29
Vss (l m
2) 81.06 ± 11.90 81.81 ± 9.76
Unbound docetaxel
Unbound fraction (fu) 7.8 ± 2.7% 8.9 ± 2.1%
fu·AUC (μg·h ml1) 0.310 ± 0.121 0.389 ± 0.114*
Neutropenia n = 33 n = 16
Percent decrease in
ANC at nadir
76.4 ± 13.2 85.2 ± 9.3*
No. of patients
Grade 4 7 (22%) 8 (50%)
#
Grade 3 9 (27%) 4 (25%)
Grade 2 9 (27%) 2 (13%)
Grade 1 4 (12%) 0
Grade 0 4 (12%) 2 (13%)
Data are shown as the mean ± standard deviation.
ANC, absolute neutrophil count; AUC, area under the concentra-
tion–time curve; CL, total body clearance; Cmax, maximum plasma
concentration; Vc, volume of distribution of the central compart-
ment; Vss, volume of distribution at steady state.
*Statistically signiﬁcant difference at P < 0.05 using the Mann–
Whitney U test.
#P < 0.05 compared between the two cohorts with or without in-
cidence of grade 4 neutropenia as assessed using the Fisher’s exact
test.
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difference in the degree of unbound fraction between pa-
tients aged <75 years and ≥75 years, as shown in Table 3.
The degree of unbound fraction weakly correlated with serum
AAG levels (R2 = 0.149, P < 0.01; Figure 3C), but not with se-
rum ALB (R2 = 0.073; Figure 3D).
Neutropenia
Thirty-three patients aged<75 years and 16 patients aged ≥75
years were assessable for neutropenia. Only one patient expe-
rienced febrile neutropenia. Percent decrease in ANC at nadir
and the number of patients with each grade of neutropenia
are summarized in Table 3. Percent decrease in ANC at nadir
was signiﬁcantly greater in patients aged ≥75 years (85.2 ±
9.3%) than in patients aged <75 years (76.4 ± 13.2%,
P < 0.05). As shown in Figure 4A, percent decrease in ANC
at nadir was related to fu·AUC, but not to total AUC
(P = 0.628, not shown). Exposure-toxicity analysis using
Eq. (4) revealed that EC50 was dependent on ANC value at
baseline, but not on age and gender (Table S2, Table 2 and
Figure 4A). In addition, the percentage of patients with grade
4 neutropenia was higher in the ≥75 years group (P < 0.05;
Table 3). The box plot in Figure 4B shows a decrease in ANC
at baseline occurs with increasing grade of neutropenia
(P < 0.05).
Discussion
Docetaxel pharmacokinetic and pharmacodynamic proﬁles
in elderly individuals are still unclear because of large
interpatient variability caused by physiological and patho-
physiological individual changes. The serum level of AAG, a
major binding protein of docetaxel, is considered to be a de-
terminant for docetaxel pharmacokinetics and pharmacody-
namics. However, there are no reports about the impact of
serum AAG on exposure and toxicity in elderly patients
treated with docetaxel. Therefore, this prospective study in-
vestigated the effects of advanced age and serum AAG level
on pharmacokinetics and related neutropenia of docetaxel
in cancer patients by assessing actual unbound drug fraction
(fu). Docetaxel CL was found to be associated with serum
AAG level regardless of age (Figure 2, Table S1 and Table 2).
AAG is an acute phase reactant, and its serum level is in-
creased in disease states such as cancer, burns and acute myo-
cardial infarction [21]. It is also known that serum ALB levels
are low in critically ill patients because of altered distribution
between intravascular and extravascular compartments [22].
Thus, decreased ALB levels might mitigate increases in AAG,
explaining why no effect is observed in some of the studies
that focus on AAG only. Therefore, the correlation between
CL and serum ALB level, observed to be signiﬁcant in univar-
iate analysis (Figure 2, Table S1), is deemed to be solely appar-
ent. ALB is a signiﬁcant covariate affecting Vc but not CL
(Table S1, Table 2). In a previous study, AAG was identiﬁed
to be a signiﬁcant predictor of total docetaxel CL, with high
AAG levels being associated with reduced total docetaxel CL
[23]. Our result is consistent with this report and veriﬁes this
relationship in a wide range of ages from 34 to 84 years. This
observation also shows that docetaxel has a low hepatic ex-
traction ratio because the unbound fraction, as determined
by AAG level (Figure 3C), correlated with total CL. In addi-
tion, moderate hepatic dysfunction has been reported to de-
crease docetaxel CL [23–25]. However, only one patient
aged <75 years had moderate hepatic dysfunction (AST
76 U l1, ALT 57 U l1) in our study, as shown in Table 1.
Figure 3
Distribution of the unbound fraction of docetaxel (A) and correlations between the degree of unbound fraction and age (B), α1-acid glycoprotein
(AAG) (C) and albumin (ALB) (D). N.S., not statistically signiﬁcant
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Therefore, the inﬂuence of hepatic function on docetaxel
pharmacokinetics was not evaluable in this patient popula-
tion. Other currently known factors of interindividual vari-
ability in docetaxel pharmacokinetics are not believed to
have major impact [26].
Generally, older NSCLC patients who received chemo-
therapy had fewer previous chemotherapy events than youn-
ger patients and were less likely to receive platinum-based
regimens. Nevertheless, older patients (aged ≥75 years) had
more adverse events during chemotherapy, independent of
comorbidity [27]. This current study of NSCLC patients
shows no age-related differences in total docetaxel pharmaco-
kinetic parameters, but higher incidence of grade 4 neutrope-
nia in patients aged ≥75 years (Table 3) despite the number of
prior treatments being fewer in older patients (Table 1). These
results are consistent with other studies in various cancer pa-
tients treated with docetaxel [10, 11]. Ten Tije et al. [10] and
Hurria et al. [11] reported no statistically signiﬁcant age-
related differences in total docetaxel pharmacokinetics; how-
ever, older patients (aged ≥65 or 75 years) experienced severe
haematological toxicity at doses of 75 mg m2 once every 3
weeks or 35 mg m2 weekly, respectively. Dosage of docetaxel
in our study was 60 mg m2 once every 3 weeks, which dif-
fered from the recommended dose of 75 mg m2 for NSCLC
in the US and Europe. There is still discrepancy in clinically
feasible standard doses for NSCLC between Japan and other
countries, as docetaxel was approved in Japan at a recom-
mended dose of 60 mg m2 once every 3 weeks based on the
results of Japanese registration studies [28–30]. There are no
racial and/or ethnic differences in docetaxel pharmacokinet-
ics, but a marked difference has been observed in toxicities
of docetaxel [31].
Unbound drugs are pharmacologically active because
they can traverse cell membranes and distribute into tissues
to bind their targets. It has been reported that exposure of un-
bound docetaxel is related to drug-induced hematologic tox-
icity [15, 16]. We illustrated that percent decrease in ANC at
nadir was related to fu·AUC (Figure 4A). Interestingly, our re-
sults indicate unbound AUC (fu·AUC) of docetaxel was signif-
icantly higher in patients aged ≥75 years than in patients
aged <75 years (Table 3), suggesting severe neutropenia in
older patients is attributable not only to high sensitivity as
concluded in previous reports, but also high unbound AUC
(fu·AUC). As serum AAG level is a determinant of CL
(Table S1, Table 2), which inversely relates to AUC, as well
as unbound fraction (fu; Figure 3C), AAG levels determine
fu·AUC and can predict docetaxel-induced neutropenia for
even older patients, with a wide degree of interindividual
variability.
Low baseline ANC patients are reportedly at an increased
risk of developing grade 4 neutropenia. We also found ANC
at baseline to be a signiﬁcant factor affecting EC50, which in
turn inﬂuenced the percent decrease in ANC induced by do-
cetaxel (Table S2, Table 2 and Figure 4A). Further, decreased
ANC at baseline correlated with development of severe neu-
tropenia (Figure 4B). Indeed, in patients aged ≥75 years whose
baseline ANC tended to be lower but not signiﬁcantly com-
pared with patients aged <75 years (Table 1), the percentage
of patients with grade 4 neutropenia was signiﬁcantly higher
(Table 3). Therefore, low ANC at baseline can predict severe
neutropenia as it is described in the clinical practice guideline
“Recommendations for the Use of WBC Growth Factors” by
the American Society of Clinical Oncology (ASCO) that pre-
existing neutropenia is one of the risk factors for febrile neu-
tropenia [32].
The ASCO guideline also recommends primary prophy-
laxis with CSF for patients with risk factors of febrile neutro-
penia including those aged ≥65 years. Increasing risk and
severity of toxicities with age can be explained in terms of de-
clining bonemarrow reserve [33], dysregulated cellular prolif-
eration, decreased ability to repair DNA, and reduced
immune surveillance. Serum ALB levels are generally de-
creased in the elderly, whereas AAG levels are not altered by
age per se [34]. However, in cancer patients, serum AAG levels
have been reported to be high and vary approximately ﬁve-
fold between individuals [35]. Indeed, serum AAG levels at
baseline varied from 50 to 264 mg dl1 (normal range;
39–98 mg dl1), and consequent degree of unbound fraction
was also widely distributed in 3.1–15.6% (Figure 3A).
In conclusion, this study indicates that serum level of
AAG is a key determinant of docetaxel unbound exposure
Figure 4
Associations between percent decrease in absolute neutrophil count
(ANC) at nadir and unbound exposure (fu·AUC) in patients aged
<75 years (○) and patients aged ≥75 years (●) (A); Solid and dashed
lines represent prediction by a sigmoid Emax model in patients with
baseline ANC ≤ 4341 μl1 and > 4341 μl1, respectively. Box plot
of neutropenia grade vs. ANC at baseline (B); Box extending from
the 25th to 75th percentile with the 50th percentile drawn inside
the box and a line extending to the 95th percentile
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and related dose-limiting toxicity regardless of ageing.
Neutropenia can be predicted by serum AAG level and ANC
at baseline for patients of all ages following the administra-
tion of docetaxel.
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